2-hydrazinocyclohexanol | 89582-25-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-hydrazinocyclohexanol
• 英文别名: (+/-)-2-hydrazinylcyclohexanol；(1R,2R)-2-Hydrazinylcyclohexanol；2-hydrazinylcyclohexan-1-ol
• CAS: 89582-25-2
• 化学式: C₆H₁₄N₂O
• 分子量: 130.19
• InChiKey: ARQGIKLKSPYVME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  58.3
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-hydrazinocyclohexanol 在 吡啶 、 溶剂黄146 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 48.5h， 生成 (1S,2S)-benzoic acid-2-((3bS,4aR)-3,4,4-trimethyl-3b,4,4a,5-tetrahydrocyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)cyclohexyl ester
  参考文献：
  名称：

  Novel optically active pyrazole ligands derived from (+)-3-carene

  摘要：

  Reactions of chiral beta -diketone with racemic hydrazines as well as reaction of chiral pyrazole with cyclohexene epoxide and trans-stilbene epoxide have been examined as the routes to optically active pyrazolylethanols. Diastereomerically pure products have been isolated by crystallization or column chromatography in good yields. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(01)00477-3
• 作为产物：
  描述：

  氧化环己烯 在 一水合肼 作用下， 反应 2.0h， 以95%的产率得到2-hydrazinocyclohexanol
  参考文献：
  名称：

  2-羟基肼基乙醇与醛和戊二醛的反应制备二氧杂六氮杂过氢蒽和-per基并进行立体化学反应。

  摘要：

  在水溶液中使肼基乙醇1与醛2和6以及戊二醛（14）反应，分别得到19-88和42-72％的二氧杂环戊二氮杂过氢蒽3、7、12、13和-per 15。通过（13）C-NMR谱推导化合物3、7、12和15具有两个C（2）对称轴，而通过X射线晶体学显示化合物12具有对称轴。最有利的立体异构体与通过半经验分子轨道方法AM1获得的预测一致。化合物15的结构通过X射线晶体学确认。

  DOI：

  10.1021/jo951878p

文献信息

• [EN] PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 DE TYPE PYRAZOLO[4,3-C]CINNOLIN-3-ONE
  申请人：MERCK SHARP & DOHME

  公开号：WO2010096338A1

  公开（公告）日：2010-08-26

  The present invention is directed to pyrazolo [4,3-c] cinnolin-3-one compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的吡唑并[4,3-c]咖啉-3-酮化合物，这些化合物是M1受体阳性变构调节剂，并且在治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面有用。该发明还涉及包含这些化合物的药物组合物，以及在治疗由M1受体介导的疾病中使用这些化合物和组合物。
• [EN] HETEROCYCLIC FUSED CINNOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS D'UN RÉCEPTEUR M1 DE CINNOLINE FUSIONNÉE HÉTÉROCYCLIQUE
  申请人：MERCK SHARP & DOHME

  公开号：WO2010123716A1

  公开（公告）日：2010-10-28

  The present invention is directed to heterocyclic fused cinnoline compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的杂环融合喹啉化合物，这些化合物是M1受体阳性变构调节剂，并且在治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面有用。该发明还涉及包含这些化合物的药物组合物，以及在治疗M1受体介导的疾病中使用这些化合物和组合物。
• [EN] M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 ET PROCÉDÉS POUR LES UTILISER
  申请人：MERCK SHARP & DOHME

  公开号：WO2017160670A1

  公开（公告）日：2017-09-21

  The present invention is directed to compounds of general formula (I) or pharmaceutically acceptable salts thereof, which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, or pharmaceutically acceptable salts thereof, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及一般式(I)的化合物或其药用盐，它们是M1受体正向变构调节剂，可用于治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。该发明还涉及包含这些化合物或其药用盐的药物组合物，以及这些化合物和组合物在治疗由M1受体介导的疾病中的用途。
• Method for producing 2-(1,2,4-Triazol-1-yl)-ethanols
  申请人：——

  公开号：US20030018201A1

  公开（公告）日：2003-01-23

  According to a novel process, microbicidally active 2-(1,2,4-triazol-1-yl)-ethanols of the formula 1 in which A 1 , A 2 , R 1 , R 2 , R 3 and R 4 are as defined in the description, can be prepared by reacting hydrazine derivatives of the formula 2 with N-dihalogenomethyl-formamidinium halide of the formula 3 in which X represents chlorine or bromine, if appropriate in the presence of a diluent.

  根据一种新的工艺，可以通过将公式1中A1、A2、R1、R2、R3和R4如描述中所定义的肼衍生物与公式3中的N-二卤甲基甲酰胺盐酸盐（其中X代表氯或溴，必要时在稀释剂存在下反应）反应，制备出具有微生物杀灭活性的2-(1,2,4-三唑-1-基)-乙醇。
• Synthesis of d-ring modified acid hydrazide derivatives of podophyllotoxin and their anticancer studies as Tubulin inhibiting agents
  作者：Srinivas Nerella、Shravankumar Kankala、Suresh Paidakula、Brahmeshwari Gavaji

  DOI：10.1016/j.bioorg.2019.103384

  日期：2020.1

  A new series (except compound 3a) of d-ring modified acid hydrazides of podophyllotoxin were synthesized by cleaving of its d-ring with various hydrazines. Furthermore, the synthesized compounds were screened for their anticancer activity against human tumor cell lines i.e., MCF-7, HeLa and A-549 and among the synthesized compounds 3c and 3f have shown significant anticancer activity almost similar

  鬼臼毒素的d环修饰酸酰肼的新系列（化合物3a除外）是通过用各种肼裂解d环而得到的。此外，对合成的化合物针对人肿瘤细胞系MCF-7，HeLa和A-549的抗癌活性进行了筛选，并且在合成的化合物3c和3f中显示出显着的抗癌活性，几乎与标准药物依托泊苷相似。还对活性化合物进行了分子建模研究，发现所获得的自由能与观察到的IC50值高度吻合。